Heart Failure, Congestive, Lymphoma
Conditions
Keywords
Lymphoma, Anthracyclines, Heart Failure, Radionuclide, Magnetic Resonance Imaging, Troponin, Natriuretic Peptide, Brain
Brief summary
Anthracycline-based chemotherapy is a key point of the treatment of patients with Hodgkin's and non-Hodgkin's lymphomas. However, cumulative doses are limited by cardiotoxicity, resulting in a marked left ventricular function impairment that may lead to heart failure. The standard clinical approach to monitoring for anthracycline cardiotoxicity is based on cardiac function monitoring using echocardiography or radionuclide angiography. The aim of this study is to evaluate the usefulness of biochemical markers of cardiac injury (troponin and NT-proBNP) and structural changes on cardiac MR in predicting anthracycline cardiotoxicity.
Interventions
None listed
Sponsors
Ligue contre le cancer, France
Centre Henri Becquerel
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Histologically proven lymphoma (Hodgkin's or non-Hodgkin's) * Age \> 18 y/o and \< 70 y/o * WHO score \< or = 2 * Life expectancy \> 6 mo * Left ventricular ejection fraction \> 50% * Informed consent
Exclusion criteria
* Previous chemotherapy using anthracyclines * History of radiation therapy * History of congestive heart failure * History of chronic renal insufficiency * Contra indication to MR examination * Atrial fibrillation and significant arrhythmia * Pregnancy
Countries
France
Outcome results
None listed